# FDA Approves BYSANTI, First New Psychiatric Drug in Years for Bipolar I and Schizophrenia

*2026-02-22 11:02 UTC · Science · 1 min read*

> FDA approves BYSANTI (milsaperidone) for bipolar I disorder and schizophrenia, a new psychiatric drug expected in pharmacies by Q3 2026.

The FDA has approved BYSANTI (milsaperidone), a new chemical entity from Vanda Pharmaceuticals, for treating manic and mixed episodes in bipolar I disorder and schizophrenia in adults. The approval, announced February 20, marks a rare addition to the atypical antipsychotic class and is expected to reach patients by Q3 2026.

BYSANTI demonstrated bioequivalence to iloperidone across the full therapeutic dosing spectrum, supported by over 100,000 patient-years of real-world safety data from Fanapt (iloperidone). Vanda is also testing the drug as a once-daily add-on for treatment-resistant major depression, with results expected by year-end.

The drug carries patent protection through 2044, giving Vanda a long commercial runway. Shares surged on the news as analysts noted the company now has back-to-back regulatory wins this year.

## Sources

- [prnewswire.com](https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-fda-approval-of-bysanti-milsaperidone-for-the-treatment-of-bipolar-i-disorder-and-schizophrenia---a-new-chemical-entity-opening-new-horizons-in-psychiatric-innovation-302693941.html)
- [investing.com](https://www.investing.com/news/company-news/fda-approves-vandas-bysanti-for-bipolar-disorder-schizophrenia-93CH-4517356)

---
TechTools News · https://techtools.cz/tools/news/article/337-fda-approves-bysanti-first-new-psychiatric-drug-in-years-for-bipolar-i-and
Česká verze: https://techtools.cz/tools/news/clanek/323-fda-schvalila-bysanti-prvni-novy-psychiatricky-lek-pro-bipolarni-poruchu-i-typu
